The Clarity™ Prenatal Test
Non-invasive access to the fetal genome, offering comprehensive microarray analysis without the risks to the fetus posed by anmiocentesis and CVS, both invasive procedures.
Isolating Fetal Cells
From fetal cells specific to the current pregnancy, isolated from a maternal blood sample, Cellscape can analyze the pure and complete fetal genome by a number of molecular techniques. CellScape uses the latest in microarray technology to generate reliable clinical results.
About CellScape
Together with some of the foremost scientists and researchers in the world, the CellScape team is bringing innovative and reliable genetic testing to the field of prenatal medicine.
Clinical Studies
CellScape is currently enrolling sites for its clinical trials. If you are interested in learning more about being a trial site, please contact us. We look forward to working with you.
Learn More
News
CellScape’s Clarity test uses noninvasive chromosomal microarray technology. A recent landmark NICHD study, authored by some of CellScape Advisors and published in the New England Journal of Medicine, describes the important value of chromosomal microarray analyses in prenatal diagnosis. The results were featured on CNN News – “New Prenatal Genetic Test Gives Parents More Answers.”
View the story on CNN.com
Contact Us
7979 Gateway Blvd., Suite 240
Newark, CA 94560
510-456-3800
info@cellscapecorp.com
Contact Form